RAMP3 Modulation of GPER1 Function in Cardiovascular Disease
RAMP3 Modulation of GPER1 Function in Cardiovascular Disease
批准号:
8224241
负责人:
Patricia Marie Lenhart-Pendergrass
金额:
$2.92万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-08-30 至 2015-08-29
关键词:
AffectAgeAgonistAmericanAngiotensin IIBindingBreedingCOS-7 CellCardiacCardiovascular DiseasesCardiovascular systemCause of DeathCell membraneCellsCessation of lifeDevelopmentDisease ProgressionDisease susceptibilityEstrogensFamilyFamily memberFemaleG-Protein-Coupled ReceptorsGenderGeneticGenetic ModelsGenotypeGoalsHealthHeartHeart DiseasesHeart HypertrophyHeart failureHumanIn VitroLeadLigandsMediatingMenopauseMusMutateN-ethylmaleimide-sensitive proteinNaturePathway interactionsPhenotypePlayProteinsRAMP3RecyclingResearch ProposalsRiskRoleSignal PathwaySignal TransductionSpecificityTestingTherapeuticTransfectionUnited StatesWomandisease phenotypeimprovedin vivointerestmalemenmouse modelnew therapeutic targetnovelpublic health relevancereceptorreceptor recyclingreceptor-activity-modifying proteinsextrafficking
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Sex-dependent differences in cardiovascular disease (CVD) susceptibility and progression may be estrogen-mediated, but the genetic pathways regulating estrogen cardioprotection have yet to be elucidated. Receptor Activity Modifying Proteins, or RAMPs, are transmembrane accessory proteins that are known to interact with G-protein coupled receptors (GPCRs) and play a role in receptor trafficking and ligand specificity. RAMP3 is unique in that it is transcriptionally induced by estrogen and CVD. Also, unlike other RAMP family members, RAMP3 is known for its ability to alter GPCR recycling to the plasma membrane through a PDZ motif-dependent association with NSF. GPER1 is a novel cardioprotective estrogen-binding GPCR that is present in increased levels in females and in CVD. Our preliminary findings have shown that genetic loss of RAMP3 leads to reduced levels of GPER1 at the plasma membrane of cardiac cells in a sex-dependent fashion, providing evidence for an interaction of RAMP3 with GPER1. We will investigate the potential interaction between RAMP3 and GPER1 in vitro using transfected cells to determine whether RAMP3 can alter GPER1 recycling to the plasma membrane. In addition we will perform in vivo studies to determine whether pharmacological activation of GPER1 signaling affects the cardiovascular phenotype of RAMP3-/- male and female mice on a genetic background of heart failure. Results from this proposal will elucidate the role of RAMP3 and GPER1 in sex-dependent cardioprotection and have the potential of identifying novel therapeutic targets for gender-tailored treatment of CVD.
PUBLIC HEALTH RELEVANCE:
Narrative Heart Disease is a common health condition that ranks as the leading cause of death for both men and women in the United States, causing over 630,000 deaths each year. This means that one out of every four deaths in the U.S. is due to heart disease. Though heart disease affects both men and women, for reasons we do not fully understand, it affects the two sexes differently. Prior to menopause, women are generally protected from heart disease while men of the same age are at increased risk in comparison. However, after menopause, a woman's risk of developing heart disease drastically increases. Sex-dependent differences in heart disease susceptibility and progression may be mediated by estrogen, but the genetic pathways that regulate this effect have not yet been clearly identified. In this research proposal we will investigate specific signaling pathways that may be involved in the sex-dependent differences of heart disease. Because heart disease is such a prevalent and serious threat to American health, these studies are important to clarify the mechanisms that underlie the development and progression of this condition, with the overall goal of improving human health.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RAMP3 Modulation of GPER1 Function in Cardiovascular Disease
-
批准号:8534242
-
项目类别:
-
资助金额:$3.42万
-
财政年份:2010
-
负责人:Patricia Marie Lenhart-Pendergrass
-
依托单位:
RAMP3 Modulation of GPER1 Function in Cardiovascular Disease
-
批准号:7997605
-
项目类别:
-
资助金额:$2.88万
-
财政年份:2010
-
负责人:Patricia Marie Lenhart-Pendergrass
-
依托单位:
RAMP3 Modulation of GPER1 Function in Cardiovascular Disease
-
批准号:8711540
-
项目类别:
-
资助金额:$2.92万
-
财政年份:2010
-
负责人:Patricia Marie Lenhart-Pendergrass
-
依托单位:
RAMP3 Modulation of GPER1 Function in Cardiovascular Disease
-
批准号:8311676
-
项目类别:
-
资助金额:$2.97万
-
财政年份:2010
-
负责人:Patricia Marie Lenhart-Pendergrass
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: